Mary Kay renews commitment to prevent, eliminate gender-based violence

 

KUALA LUMPUR, Nov 25 -- Mary Kay Inc and the Mary Kay Ash Foundation have announced a renewed, joint commitment to the prevention and elimination of gender-based violence by joining the Generation Equality Action Coalition on Gender-Based Violence.

This is in recognition of the upcoming International Day for the Elimination of Violence against Women kicking off the 16 Days of Activism against Gender-Based Violence, according to a statement.

The commitment—which the organisations made public during UN Women’s recent Generation Equality Forum in Paris—is just the latest step the storied beauty brand and its charitable arm have made in the interest of improving the lives of women everywhere.

The Action Coalition on Gender-Based Violence, co-led by UN Women and by the UN Trust Fund to End Violence against Women (UN Trust Fund), among other leaders, is a powerful global movement mobilising governments, international organisations, philanthropies, and the private sector to deliver transformational progress towards the elimination of gender-based violence through four concrete actions.

This includes creating enabling policy, legal and resource environments; scaling up evidence driven prevention programming; scaling up comprehensive, accessible, and quality services for survivors; and, enabling and empowering autonomous girl-led and women’s rights organisations to exercise their expertise.

A goal of the Generation Equality Gender-Based Violence Action Coalition is to have 550 million more women and girls live in countries with laws and policies prohibiting all forms of gender-based violence against women and girls by 2026, among others.

During the Forum, UN Women committed to amplifying support and funding to women’s rights organisations by working with partners to secure a minimum of US$100 million in grants to be allocated through the UN Trust Fund to End Violence against Women (UN Trust Fund) over the next five years. (US$1 = RM4.213)

Last year, Mary Kay Inc and the Mary Kay Ash Foundation joined forces with the United Nations Trust Fund to End Violence against Women (UN Trust Fund) and CARE, two champions of women’s rights, to further their mission to achieve a world free from violence against women.

-- BERNAMA

MILREM ROBOTICS LED IMUGS CONSORTIUM DEMONSTRATES DEPLOYMENT OF UNMANNED SYSTEMS

 

Two THeMIS UGVs during the iMUGS Demonstration. One THeMIS UGV is equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT), Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The second THeMIS, used as a mule for transporting the squad’s equipment, is equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular. (Photo: Business Wire) 

ĀDAŽI, Latvia, Nov 25 (Bernama-BUSINESS WIRE) -- The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions. 

The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.

Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.

One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.

The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.

The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.

In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.

“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.

''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.

Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).

The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.

The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.

The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.

iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.

Watch the Demo 2 Scenarios here:

https://www.youtube.com/watch?v=-_iLCV3Ob2I

https://www.youtube.com/watch?v=HbK_ixrTuWU 

View source version on businesswire.com: 
https://www.businesswire.com/news/home/52539351/21

Contact

Gert Hankewitz
Milrem Robotics
gert.hankewitz@milrem.com 

Source : Milrem Robotics

--BERNAMA

OAG new Flight Info Alerts soars

KUALA LUMPUR, Nov 17 -- OAG, the world’s leading provider of travel data and insight, has announced the launch of Flight Info Alerts, its new detection and notification product that delivers changes to flight schedules in real-time.

In response to customer demands for a fast and reliable feed which expedites vital changes, it is the only product on the market that enables customers to get instant updates on carrier flight schedules so they can handle data volatility in real-time.

“Alerts is a much-needed solution for our customers who manage bookings or operations and anyone who relies on the accuracy of these vital changes to drive their business.

“Volatility of this data over the last 18 months has become an increasing challenge, so our customers need us to tell them what’s changed in real-time.

“We’re innovating rapidly to meet the changing needs of the travel sector. Our investment in OAG Metis and great tech partnerships with Snowflake and Microsoft Azure enable us to serve the entire ecosystem to scale and serve multiple markets rapidly and efficiently,” said OAG CEO, Phil Callow in a statement.

OAG’s Flight Info Alerts launch is the latest in a wave of new product innovations powered by its new technology platform, OAG Metis, which saw the release of Flight Info Direct, a Snowflake enabled platform to access and integrate ready to query data, earlier this year.

The evolution and ambition of OAG’s Flight Info API continues to gather pace to equip customers with data covering the full flight and booking journey, with the imminent availability of Flight Status Data into the API suite. Access through a singular API enables OAG customers to innovate, react faster and scale quicker.

For more information, visit: www.oag.com

-- BERNAMA

Celltrion secures CHMP positive opinion for regdanvimab (CT-P59) over COVID-19 treatment

KUALA LUMPUR, Nov 15 -- Celltrion Group has announced the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59).

regdanvimab (CT-P59) is a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union, according to a statement.

“We have accumulated the safety and efficacy data of regdanvimab in the treatment of patients infected with COVID-19 and its associated variant strains, including the more virulent Delta variant,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.

“At Celltrion, we are proud to play our part in tackling the unprecedented global threat of COVID-19 and believe regdanvimab offers an important addition to the treatment arsenal.”

The positive CHMP opinion was supported by data from the global Phase III clinical trial in which Celltrion enrolled more than 1,315 people to evaluate the efficacy and safety of regdanvimab in 13 countries including the US, Spain, and Romania.

Data showed regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72 per cent for patients at high-risk of progressing to severe COVID-19.

Rolling review of regdanvimab had been initiated by the EMA in February this year and the announcement of the CHMP positive opinion for regdanvimab follows the submission of a marketing authorisation application (MAA) to the EMA seeking approval of regdanvimab in October.

More details at https://www.celltrionhealthcare.com/en-us.

-- BERNAMA

NCSOFT: Lineage W new commercial features 'Game of Thrones' star Kit Harington

 

KUALA LUMPUR, Nov 5 -- NCSOFT, a global premier game developer and publisher, has revealed a new commercial of the company’s multi-platform MMORPG, ‘Lineage W’.

Lineage W’s new TV commercial and digital ad which features ‘Game of Thrones’ star Kit Harington delivering an epic speech to his Blood Brethren before battle, emphasises Lineage’s core values: battle, Blood Pledge, sacrifice, and honour.

According to a statement, the commercial is being aired on TV in selected regions and is available on the official website and Lineage W YouTube.

Lineage W is now available for play in 12 countries and regions, including Korea, Taiwan, Japan, Southeast Asia, and the Middle East.

NCSOFT will expand service regions to North America, South America, Europe, and Russia in the near future. Players can download Lineage W on iOS devices, Android devices, and PC (via PURPLE, NCSOFT’s proprietary PC cross-play service).

-- BERNAMA

MINISTRY OF ENVIRONMENT HOLDING EXHIBITIONS AND SEMINARS AT JAPAN PAVILION AT COP 26

TOKYO, Nov. 5, 2021 /Kyodo JBN-AsiaNet/ --

The Ministry of the Environment, Japan (MOEJ), has set up the Japan Pavilion at the venue of COP 26 (the 26th Conference of the Parties to the United Nations Framework Convention on Climate Change), underway in Glasgow, the United Kingdom, from October 31 to November 12, 2021. The Pavilion provides the opportunity for Japanese stakeholders including companies to organize exhibitions and seminars. MOEJ is also organizing the Virtual Japan Pavilion to showcase technologies and actions online. - Overview of Japan Pavilion at COP 26 During COP 26, MOEJ is operating the Japan Pavilion to hold exhibitions and seminars, as well as the Virtual Japan Pavilion, which showcases technologies and actions, in order to introduce Japan's initiatives and environmental technologies to achieve global and domestic decarbonization. On July 20, 2021, MOEJ issued a call for applications to exhibit advanced decarbonization technologies at the Japan Pavilion, and selected 12 on-site exhibits as well as 33 virtual exhibits (as shown in Attachment 1). In addition, seminars listed in Attachment 2 are being held at the Japan Pavilion. Detailed information for the exhibitions and seminars has been posted on the following website. - COP 26 Japan Pavilion Website: http://copjapan.env.go.jp/cop/cop26/en/index.html Attachment 1: List of Pavilion exhibitions https://kyodonewsprwire.jp/attach/202111022694-O1-QeC4v9P7.pdf Attachment 2: Tentative seminar schedule https://kyodonewsprwire.jp/attach/202111022694-O2-30sBDuM5.pdf Source: Ministry of the Environment --BERNAMA

TESSA THERAPEUTICS ANNOUNCES PRESENTATION OF AUTOLOGOUS AND ALLOGENEIC CELL THERAPY DATA AT 2021 ASH ANNUAL MEETING

Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomas

SINGAPORE, Nov 5 (Bernama-GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that data from its ongoing autologous and allogeneic cell therapy studies targeting lymphomas has been accepted for two separate poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 11-14, 2021.

The presentations include clinical data from a Phase II multi-center study evaluating safety and efficacy of CD30 CAR-T therapy (TT11) in patients with relapsed / refractory classical Hodgkin Lymphoma (R/R cHL) and another Phase I investigator-initiated study testing allogeneic ‘off-the-shelf’ CD30 CAR EBVST therapy (TT11X) in patients with relapsed / refractory CD30+ lymphoma. Accepted abstracts will also be published online in the November supplemental issue of Blood, a publication of the American Society of Hematology.

Details of Presentations

Title: Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Session Name: 704. Cellular Immunotherapies: Clinical: Poster III
Abstract: #3847
Presenting Author: Sairah Ahmed, M.D., MD Anderson Cancer Centre
Date, Time and Location: December 13, 2021; 6:00 PM - 8:00 PM ET; Georgia World Congress Center, Hall B5

Title: Safety and efficacy of off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells in patients with CD30-positive lymphoma
Session Name: 704. Cellular Immunotherapies: Clinical: Poster I
Abstract: #1763
Presenting Author: David Hon Quach, Instructor, Center for Gene Therapy, Baylor College of Medicine, Houston, TX
Date, Time and Location: December 11, 2021; 5:30 PM - 7:30 PM ET; Georgia World Congress Center, Hall B5

About TT11 (CD30 CAR-T Therapy)

TT11 is a CAR-T therapy, which harvests a patient’s own T-cells and modifies them by introducing a CD30-directed Chimeric Antigen Receptor (CAR) to target and kill CD30+ cells in classical Hodgkin Lymphoma (cHL). CD30 is a well validated lymphoma target with homogeneous expression in 98% of cHL and a significant proportion of subsets of non-Hodgkin Lymphomas. Clinical data from two Phase 1/2 studies, published last year in the Journal of Clinical Oncology^a, showed TT11 demonstrated strong safety and efficacy as a monotherapy for heavily pre-treated R/R cHL patients. A Phase 2 study was subsequently conducted this year evaluating TT11 among R/R cHL patients, results for which will be presented at 2021 ASH annual meeting.

About TT11X (Allogeneic CD30 CAR-EBVST Therapy)

TT11X is an allogeneic ‘off-the-shelf’ therapy which augments Epstein bar virus-specific T-cells with CD30 CAR technology. The therapy is based on a proprietary allogeneic cell therapy platform developed from decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by Tessa’s Scientific Co-Founder, Dr. Malcolm Brenner, and the team at Baylor College of Medicine. VSTs are highly specialized T cells with the ability to recognize and kill infected cells while activating other parts of the immune system for a coordinated response. Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of GVHD. Preclinical studies have further demonstrated that CD30 targeting potentially helps improve allogeneic cell expansion and persistence. With this platform approach, Tessa aims to overcome the current challenges faced by allogeneic cell therapies and create more efficacious, reliable, and scalable therapies capable of targeting a broad range of cancers.

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (Phase 2). TT11 has been granted RMAT designation by the FDA and PRIME designation by European Medicine Agency. Tessa is also advancing an allogeneic “off-the shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR technology to prevent graft rejection. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphoma. A third clinical asset evaluates novel combination therapy of HER2-CAR-T cells and binary oncolytic virus in an ongoing Phase 1 study targeting HER2 positive solid tumors. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. Tessa’s United States headquarters are in New Jersey. For more information on Tessa, visit www.tessacell.com.

Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body.

References:
a. Ramos et al., J Clin Oncol 2020

Tessa Therapeutics Media Contact
Ritika Khetawat
+65 6384 0755
media@tessacell.com

Source: Tessa Therapeutics Ltd

--BERNAMA